RAQUALIA PHARMA INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 596 JPY | +0.17% |
|
-2.13% | -13.37% |
| Sales 2024 * | 3.83B 24.23M 33.38M | Sales 2025 * | - | Capitalization | 12.87B 81.49M 112M |
|---|---|---|---|---|---|
| Net income 2024 * | 875M 5.54M 7.63M | Net income 2025 * | - | EV / Sales 2024 * | 3.36 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
14.2
x | P/E ratio 2025 * |
-
| Employees | 67 |
| Yield 2024 * |
0.67% | Yield 2025 * |
-
| Free-Float | 78.66% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.17% | ||
| 1 week | -2.13% | ||
| Current month | -3.56% | ||
| 1 month | -4.33% | ||
| 3 months | -9.56% | ||
| 6 months | -11.18% | ||
| Current year | -13.37% |
1 week
590.00
623.00
1 month
587.00628.00
Current year
587.00705.00
1 year
587.00943.00
3 years
587.001 421.00
5 years
587.001 735.00
10 years
240.003 320.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 52 | 13-12-31 | |
Shuzo Watanabe
BRD | Director/Board Member | 57 | 08-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 76 | 20-03-25 | |
Shuzo Watanabe
BRD | Director/Board Member | 57 | 08-06-30 |
Yuichi Kakinuma
BRD | Director/Board Member | 46 | 21-03-24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-01 | 596 | +0.17% | 55 600 |
| 24-04-30 | 595 | 0.00% | 56,000 |
| 24-04-26 | 595 | -1.49% | 95,100 |
| 24-04-25 | 604 | -1.79% | 79,300 |
| 24-04-24 | 615 | +0.99% | 104,600 |
Delayed Quote Japan Exchange, May 01, 2024 at 12:30 am
More quotes
RaQualia Pharma Inc. is a Japan-based company engaged in the research and development of pharmaceutical products. The Company is mainly engaged in the discovery and research, the preclinical trials and part of clinical trials of drugs, as well as the licensing of developed compounds to pharmaceutical companies. The Company is focused on pain diseases area and intestinal disease area. Its products include EP4 antagonist, cyclooxygenase-2 (COX-2) inhibitory, 5-HT4 portion partial agonist, among others.
Sector
Pharmaceuticals
Calendar
2024-05-14
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
595
JPY
Average target price
1,800
JPY
Spread / Average Target
+202.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.37% | 81.71M | |
| +34.00% | 704B | |
| +29.29% | 577B | |
| -7.75% | 348B | |
| +18.53% | 327B | |
| +4.95% | 288B | |
| +13.79% | 234B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -4.89% | 147B |
- Stock Market
- Equities
- 4579 Stock
